Comparison of the efficacy of Albuvirtide antiretroviral therapy regimen and traditional antiretroviral therapy regimen in the treatment of newly treated severe AIDS patients
Objective To compare the efficacy of Albuvirtide antiretroviral therapy(ART)regimen and traditional ART regimen in the treatment of newly treated severe AIDS patients.Methods Sixty patients with severe AIDS who received initial treatment at the Infection Department of Ganzhou Fifth People's Hospital from July 2020 to August 2022 were selected as the research subjects.They were divided into a control group and an observation group based on treatment methods,with 30 patients in each group.The control group patients were treated with the traditional ART regimen,while the observation group patients were treated with the Albuvirtide ART regimen.The clinical efficacy,immune function(T lymphocytes[CD3+,CD4+,CD8+,CD4+/CD8+]),quality of life(World Health Organization quality of life questionnaire for HIV brief version[WHOQOL-HIVBREF])and the incidence of adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in HIV RNA load between the two groups of patients(P＞0.05).After treatment,the HIV RNA load of both groups of patients was lower than before treatment,and the observation group was lower than the control group,with a statistically significant difference(P＜0.05).Before treatment,there were no statistically significant differences in the levels of CD3+,CD4+,CD8+,and CD4+/CD8+between the two groups of patients(P＞0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+in both groups were higher than before treatment and the observation group was higher than the control group.The levels of CD8+were lower than before treatment and the observation group was lower than the control group,with a statistically significant difference(P＜0.05).Before treatment,there was no statistically significant difference in the WHOQOL-HIVBREF scores between the two groups of patients(P＞0.05).After treatment,the WHOQOL-HIVBREF scores of both groups of patients were higher than before treatment and the observation group was higher than the control group,with statistically significant difference(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion For newly diagnosed severe AIDS patients,using the Albuvirtide ART regimen and traditional ART regimen has good safety,better virus inhibition,and is more conducive to enhancing patient immune function,improving quality of life,and establishing clinical promotion and use.
Initial treatment of severe AIDSAlbuvirtideAntiretroviral treatment planimmunityQuality of Life
万方数据
维普
